Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers

Innate immune cells constitute a plastic and heterogeneous cell population of the tumor microenvironment. Because of their high tumor infiltration and close interaction with resident tumor cells, they are compelling targets for anti-cancer therapy through either ablation or functionally reprogrammin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chunying Peng, Katrin Rabold, Willem J. M. Mulder, Martin Jaeger, Romana T. Netea-Maier
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	kinase inhibitors immune checkpoint inhibitors VEGFR immunogenic cell death pyroptosis tumor-associated macrophages Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1c291d0ab5dc42928319113e43fdfc1b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1c291d0ab5dc42928319113e43fdfc1b
record_format	dspace
spelling	oai:doaj.org-article:1c291d0ab5dc42928319113e43fdfc1b2021-11-25T17:02:45ZKinase Inhibitors’ Effects on Innate Immunity in Solid Cancers10.3390/cancers132256952072-6694https://doaj.org/article/1c291d0ab5dc42928319113e43fdfc1b2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5695https://doaj.org/toc/2072-6694Innate immune cells constitute a plastic and heterogeneous cell population of the tumor microenvironment. Because of their high tumor infiltration and close interaction with resident tumor cells, they are compelling targets for anti-cancer therapy through either ablation or functionally reprogramming. Kinase inhibitors (KIs) that target aberrant signaling pathways in tumor proliferation and angiogenesis have been shown to have additional immunological effects on myeloid cells that may contribute to a protective antitumor immune response. However, in patients with malignancies, these effects are poorly described, warranting meticulous research to identify KIs’ optimal immunomodulatory effect to support developing targeted and more effective immunotherapy. As many of these KIs are currently in clinical trials awaiting approval for the treatment of several types of solid cancer, we evaluate here the information on this drug class’s immunological effects and how such mechanisms can be harnessed to improve combined treatment regimens in cancer.Chunying PengKatrin RaboldWillem J. M. MulderMartin JaegerRomana T. Netea-MaierMDPI AGarticlekinase inhibitorsimmune checkpoint inhibitorsVEGFRimmunogenic cell deathpyroptosistumor-associated macrophagesNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5695, p 5695 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	kinase inhibitors immune checkpoint inhibitors VEGFR immunogenic cell death pyroptosis tumor-associated macrophages Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	kinase inhibitors immune checkpoint inhibitors VEGFR immunogenic cell death pyroptosis tumor-associated macrophages Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Chunying Peng Katrin Rabold Willem J. M. Mulder Martin Jaeger Romana T. Netea-Maier Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
description	Innate immune cells constitute a plastic and heterogeneous cell population of the tumor microenvironment. Because of their high tumor infiltration and close interaction with resident tumor cells, they are compelling targets for anti-cancer therapy through either ablation or functionally reprogramming. Kinase inhibitors (KIs) that target aberrant signaling pathways in tumor proliferation and angiogenesis have been shown to have additional immunological effects on myeloid cells that may contribute to a protective antitumor immune response. However, in patients with malignancies, these effects are poorly described, warranting meticulous research to identify KIs’ optimal immunomodulatory effect to support developing targeted and more effective immunotherapy. As many of these KIs are currently in clinical trials awaiting approval for the treatment of several types of solid cancer, we evaluate here the information on this drug class’s immunological effects and how such mechanisms can be harnessed to improve combined treatment regimens in cancer.
format	article
author	Chunying Peng Katrin Rabold Willem J. M. Mulder Martin Jaeger Romana T. Netea-Maier
author_facet	Chunying Peng Katrin Rabold Willem J. M. Mulder Martin Jaeger Romana T. Netea-Maier
author_sort	Chunying Peng
title	Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
title_short	Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
title_full	Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
title_fullStr	Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
title_full_unstemmed	Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
title_sort	kinase inhibitors’ effects on innate immunity in solid cancers
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/1c291d0ab5dc42928319113e43fdfc1b
work_keys_str_mv	AT chunyingpeng kinaseinhibitorseffectsoninnateimmunityinsolidcancers AT katrinrabold kinaseinhibitorseffectsoninnateimmunityinsolidcancers AT willemjmmulder kinaseinhibitorseffectsoninnateimmunityinsolidcancers AT martinjaeger kinaseinhibitorseffectsoninnateimmunityinsolidcancers AT romanatneteamaier kinaseinhibitorseffectsoninnateimmunityinsolidcancers
_version_	1718412762363723776

Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers

Ejemplares similares